German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing ...

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic ...

Merck KGaA reduced its outlook for sales and profit growth this year, citing the impact of a weak US dollar and uncertainty ...

German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

As for safety, experts interviewed for this story said they are extremely confident in the systems set up to monitor vaccine ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for Merck (NYSE:MRK) from Buy to Neutral. Analyst ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...